Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

SLP - Simulations Plus, Inc. Последние новости | Finranks

Home

SLP

S

Simulations Plus, Inc. (SLP)

NMS – Цена в реальном времени. Валюта: USD

11.42

-0.28 (-2.39%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

11.42

0.00 (0.00%)

После закрытия: Mar 27, 2026, 4:10 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date

Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report second quarter fiscal 2026 financial results after the market close on Thursday, April 9, 2026. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and.

Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling

Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence (AI) workflows across the drug development lifecycle. These programs apply AI within scientifically grounded modeling workflows and define how n.

Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD

Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a high-impact panel discussion, “From Debate to Deployment: Responsible, Practical AI in MIDD,” to be held during the upcoming American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting on March 5, 2026 at 12:00 PM MST in Denver.

ROSEN, A LONGSTANDING FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

ROSEN, A LONGSTANDING FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

New York, New York--(Newsfile Corp. - February 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Simulations Plus securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations

Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the extension of two separate research collaborations with the U.S. Food and Drug Administration (FDA) and the National Institute of Environmental Health Sciences (NIEHS). The extended projects support ongoing federal research efforts focused on the deve.

ROSEN, A TOP-RANKED LAW FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

ROSEN, A TOP-RANKED LAW FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

New York, New York--(Newsfile Corp. - February 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Simulations Plus securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP

NEW YORK, Feb. 8, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. So What: If you purchased Simulations Plus securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Видео

No Data

There is no data to display